The Advent of Biosimilar Therapies in Rheumatology--"O Brave New World"

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2012 Jun 6

PMID 22664834

Citations 32

Authors

Morton A Scheinberg

Jonathan Kay

Affiliations

Soon will be listed here.

Abstract

Patents for many key biological agents will soon expire. Third-party companies are, therefore, in the process of developing their own versions, termed biosimilar agents, of these innovator products. However, manufacture of biosimilar agents is complicated by the requirement for their production in biological systems, small variations in which can influence the structure, activity and metabolism of the biosimilar product. The development of biosimilar therapies for the treatment of patients with rheumatic diseases could potentially result in substantial cost savings for patients and health care providers, and consequently, increased availability of effective therapies. However, legislation that regulates the manufacture, registration and approval of biosimilar therapies varies considerably between different countries. In addition, major safety and efficacy concerns must be addressed before a rheumatologist can routinely substitute an innovator pharmaceutical with a biosimilar product.

Citing Articles

Monga A, Gagan , Jamwal P, Sharma S, Kaur A AAPS PharmSciTech. 2025; 26(1):46.

PMID: 39870890 DOI: 10.1208/s12249-025-03038-2.

Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.

Ingrasciotta Y, Jin Y, Foti S, Landon J, Tari M, Mattace-Raso F Clin Rheumatol. 2022; 42(4):1047-1059.

PMID: 36534353 PMC: 10017582. DOI: 10.1007/s10067-022-06478-4.

The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study.

Fahmi H, Al-Jumaili A, Younus M Explor Res Clin Soc Pharm. 2022; 7:100162.

PMID: 35991683 PMC: 9386114. DOI: 10.1016/j.rcsop.2022.100162.

Real-world data on the infliximab biosimilar CT-P13 (Remsima) in inflammatory bowel disease.

Huguet J, Cortes X, Bosca-Watts M, Aguas M, Maroto N, Marti L World J Clin Cases. 2022; 9(36):11285-11299.

PMID: 35071559 PMC: 8717518. DOI: 10.12998/wjcc.v9.i36.11285.

Yisaipu Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation.

Lu H, Wang Y, Wang X, Wu X, Zhou L, Lin L Front Pharmacol. 2021; 12:692768.

PMID: 34552481 PMC: 8450409. DOI: 10.3389/fphar.2021.692768.

References

Hechavarria Nunez Y, Perez Massipe R, Orta Hernandez S, Martinez Munoz L, Jacobo Casanueva O, Perez Rodriguez V . The regulatory framework for similar biotherapeutic products in Cuba. Biologicals. 2011; 39(5):317-20. DOI: 10.1016/j.biologicals.2011.08.005. View

Dranitsaris G, Amir E, Dorward K . Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011; 71(12):1527-36. DOI: 10.2165/11593730-000000000-00000. View

Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B . The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov. 2007; 6(6):437-42. DOI: 10.1038/nrd2307. View

Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R . Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011; 29(4):310-2. DOI: 10.1038/nbt.1839. View

Kozlowski S, Woodcock J, Midthun K, Sherman R . Developing the nation's biosimilars program. N Engl J Med. 2011; 365(5):385-8. DOI: 10.1056/NEJMp1107285. View

Liang C, Wang J . China's perspective on similar biotherapeutic products. Biologicals. 2011; 39(5):312-6. DOI: 10.1016/j.biologicals.2011.06.020. View

Mellstedt H, Niederwieser D, Ludwig H . The challenge of biosimilars. Ann Oncol. 2007; 19(3):411-9. DOI: 10.1093/annonc/mdm345. View

Kessler M, Goldsmith D, Schellekens H . Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006; 21 Suppl 5:v9-12. DOI: 10.1093/ndt/gfl476. View

Kay J . Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011; 13(3):112. PMC: 3218870. DOI: 10.1186/ar3310. View

10.

Knezevic I, Griffiths E . Biosimilars--global issues, national solutions. Biologicals. 2011; 39(5):252-5. DOI: 10.1016/j.biologicals.2011.09.005. View

11.

Barosi G, Bosi A, Abbracchio M, Danesi R, Genazzani A, Corradini P . Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011; 96(7):937-42. PMC: 3128210. DOI: 10.3324/haematol.2011.041210. View

12.

Hyrich K, Lunt M, Watson K, Symmons D, Silman A . Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2006; 56(1):13-20. DOI: 10.1002/art.22331. View

13.

Schellekens H, Moors E . Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010; 28(1):28-31. DOI: 10.1038/nbt0110-28. View

14.

Maity S, Ullanat R, Lahiri S, Shekar S, Sodhan G, Vyas A . A non-innovator version of etanercept for treatment of arthritis. Biologicals. 2011; 39(6):384-95. DOI: 10.1016/j.biologicals.2011.08.014. View

15.

Malhotra H . Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals. 2011; 39(5):321-4. DOI: 10.1016/j.biologicals.2011.06.018. View

16.

Castanheira L, Barbano D, Rech N . Current development in regulation of similar biotherapeutic products in Brazil. Biologicals. 2011; 39(5):308-11. DOI: 10.1016/j.biologicals.2011.06.021. View

17.

McCamish M, Woollett G . Worldwide experience with biosimilar development. MAbs. 2011; 3(2):209-17. PMC: 3092622. DOI: 10.4161/mabs.3.2.15005. View